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Abstract
Background: Since July 2004, routine varicella vaccination is recommended by the German Standing Vaccination
Committee in Germany. Health Insurance Funds started to cover vaccination costs at different time points between
2004 and 2006 in the Federal States. Nationwide representative data on vaccination coverage against varicella of
children under two years of age are not available. We aimed to determine varicella vaccination coverage in
statutory health insured children under two years of age in twelve German Federal States using data from
associations of statutory health insurance physicians (ASHIPs), in order to investigate the acceptance of the
recommended routine varicella vaccination programme.
Methods: We analysed data on varicella vaccination from 13 of 17 ASHIPs of the years 2004 to 2007. The study
population consisted of all statutory health insured children under two years of age born in 2004 (cohort 2004) or
2005 (cohort 2005) in one of the studied regions. Vaccination coverage was determined by the number of children
vaccinated under 2 years of age within the study population.
Results: Varicella vaccination coverage of children under two years of age with either one dose of the monovalent
varicella vaccine or two doses of the measles, mumps, rubella, and varicella vaccine increased from 34% (cohort
2004) to 51% (cohort 2005) in the studied regions (p < 0.001). More than half of the vaccinated children of cohort
2004 and two third of cohort 2005 were immunised at the recommended age 11 to 14 months. The level of
vaccination coverage of cohort 2004 was significantly associated with the delay in introduction of cost coverage
since the recommendation of varicella vaccination (p < 0.001).
Conclusions: Our study shows increasing varicella vaccination coverage of young children, indicating a growing
acceptance of the routine varicella vaccination programme by the parents and physicians. We recommend further
monitoring of vaccination coverage using data from ASHIPs to investigate acceptance of the routine vaccination
programmes over time.
Background
In May 2004, a consensus statement on varicella vacci-
nation policy was published by the European Working
group on Varicella (Eurovar) [1]. Routine varicella vacci-
nation for children during early childhood and catch-up
vaccination for adolescents and adults without history of
varicella were recommended for countries where high
vaccination coverage could be anticipated. Vaccination
policies differ considerably between countries [2,3]. In
the United States, varicella vaccination is part of the
childhood immunization schedule since 1996 and the
vaccination programme had been proven to effectively
reduce varicella incidence and hospitalization rates [4,5].
In Europe, vaccination of children or adolescents against
varicella is included in national immunization schedules
of eight countries. Target groups of vaccination pro-
grammes are mainly high risk groups or children with
no history of varicella disease e.g. in Austria, Spain and
Switzerland.
Germany is one of the countries where routine vacci-
nation of all children in early childhood is recom-
mended as well as e.g. Latvia, Greece and three regions
of Italy [6,7]. Routine varicella vaccination was recom-
mended by the German Standing Committee on Vacci-
nation (STIKO) in 2004 after studies had shown a
higher rate of complications in infants and young
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According to the national immunization schedule 2004,
children should be immunised with one dose of varicella
vaccine at age 11 to 14 months. Unvaccinated older
children and adolescents without history of varicella
were also scheduled for vaccination [8]. Children are
usually vaccinated by their paediatrician. Since vaccina-
tions are voluntary in Germany, physicians play a major
role in advising parents on vaccination programmes and
in reminding them of upcoming vaccinations for their
children according to the schedule [11]. Aim of the rou-
tine varicella vaccination programme was to reduce vari-
cella morbidity, including complications and
hospitalisations [8].
Health Insurance Funds started to cover costs for vari-
cella vaccination at different time points between 2004
and 2006 in the Federal States, depending on agree-
ments with the ASHIPs. Since 2007, Health Insurance
Funds are obliged by law to cover costs for vaccinations
recommended by the STIKO and approved by the Fed-
eral Joint Committee [12].
Given that varicella is not a notifiable disease in Ger-
many, a nationwide sentinel surveillance system was
established by the Working Group on Measles and Vari-
cella (AGMV) in 2005 to monitor trends in the number
of varicella vaccinations and varicella cases [13]. The
sentinel system is based on reports from a sample of
voluntarily participating physicians which treat an unde-
fined proportion of the population because patients are
free to choose their physician. Hence population-based
varicella incidence and vaccination coverage can not be
estimated from sentinel data.
Representative nationwide data on vaccination cover-
age of children under two years of age are not available
in Germany. Yet, they are particularly important because
children should be fully immunized at the age of two
years. Therefore, the Robert Koch Institute (RKI)
initiated a project for the surveillance of vaccine preven-
table infectious diseases and vaccinations using data
from the Associations of Statutory Health Insurance
Physicians (ASHIPs) in 2004.
The main objective of our study was to determine var-
icella vaccination coverage of children under the age of
two years in order to investigate the acceptance of the
routine varicella vaccination programme in Germany.
Furthermore, we aimed to assess if children were vacci-
nated at the recommended age.
Methods
Statutory health insurance data
Physicians who treat statutory health insured persons
(approximately 87% of the population) have to report
their provided services quarterly to their ASHIP in
order to receive payment for their services from Health
Insurance Funds. Vaccinations are recorded using speci-
fic codes for reimbursement.
Since the establishment of the surveillance project in
2004, ASHIPs send anonymous data on varicella vacci-
nations to the RKI. Data are not publicly available.
Q u a l i t ya s s u r a n c eo fd a t aw a sd o n ea c c o r d i n gt ot h e
good practice secondary data analysis [14]. During
import into a database, data are tested with regard to
structure, completeness and plausibility [15]. Data
include demographic characteristics of the children
(month and year of birth, sex, district of residence),
information on the vaccination (type of vaccination, date
of vaccination) and information on medical contact
(medical specialisation of physician, district of physi-
cian’s office).
Analysis
We analysed anonymous data of the years 2004 to 2007
from 13 of 17 ASHIPs: Bavaria, Brandenburg, Bremen,
Hamburg, Lower Saxony, Mecklenburg-Western Pomer-
ania, North Rhine, Saarland, Saxony-Anhalt, Saxony,
Schleswig-Holstein, Thuringia and Westphalia-Lippe.
The regions correspond to 12 of 16 Federal States. Data
from Baden-Württemberg, Berlin, Hesse and Rhineland
Palatinate were not available for the whole four year
period and were therefore excluded from the analysis.
Study population
The study population consisted of all statutory health
insured children under two years of age born in 2004
(cohort 2004) or 2005 (cohort 2005) in one of the 13
above mentioned ASHIPs. The total number of statu-
tory health insured children under two years of age
was 415078 in 2004 (85% of all children born in 2004)
and 404988 children in 2005 (86% of all children born
in 2005) in the studied regions [16-18]. Cohort 2004
was followed-up for 36 months, cohort 2005 for
24 months.
Varicella vaccination coverage
Vaccination coverage was determined by the proportion
of children vaccinated against varicella under two years
of age within the study population. For cohort 2004,
additionally the vaccination coverage of children under
three years of age was determined. A combined measles,
mumps, rubella, and varicella (MMRV) vaccine became
available in 2006. According to the manufacturer’s
instructions two doses are required for immunisation,
preferably with a minimum of six weeks between the
two doses [19]. Children who received one dose of
monovalent varicella vaccine or two doses of MMRV
vaccine within the first two years of life were defined as
vaccinated according to the recommendations of
STIKO.
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Differences in varicella vaccination coverage between
cohort 2004 and cohort 2005 were analysed using
uncorrected chi-square statistic. Correlation between
level of vaccination coverage and date of introduction of
cost coverage for varicella vaccination by Health Insur-
ance Funds was analysed by Spearman’s rank correlation
coefficient with STATA 10 (StataCorp, Texas, USA).
Results
Varicella vaccination coverage
At the age of 24 months, 34% of children of cohort 2004
and 51% of children of cohort 2005 are vaccinated
against varicella according to the recommendations of
STIKO (Table 1). Vaccination coverage varies greatly
between regions. Regarding cohort 2004, the minimum
vaccination coverage is found in Bremen (8%) and the
maximum in Saxony-Anhalt (69%). Regarding cohort
2005, the minimum vaccination coverage is found in
Bremen (21%) and the maximum in Saarland (82%).
Children in Federal States of former East Germany have
higher varicella vaccination coverage than children in
Federal States of former West Germany (p < 0.001 for
both cohorts). In most countries, vaccination coverage
of cohort 2005 is significantly higher than vaccination
coverage of cohort 2004. However in Mecklenburg Wes-
tern-Pomerania, North Rhine and Saxony-Anhalt vacci-
nation coverage is lower in cohort 2005.
Type of varicella vaccine and age of vaccinated children
Within their first two years of life, children of both
cohorts were mainly immunised with one dose of vari-
cella monovalent vaccine in the studied regions (Table
2). Around 9% of children of cohort 2005 were vacci-
nated with two doses of the MMRV vaccine. Vaccina-
tions of both cohorts were mainly given by
paediatricians (95%) and general practitioners (4 to 5%).
For those children who received two doses of MMRV
vaccine, the median time between the doses was
28 weeks for cohort 2004 (inter quartile range (IQR):
7 to 31 weeks) and 15 weeks for cohort 2005 (IQR: 9 to
25 weeks).
77159 from 139972 (55%) vaccinated children of
cohort 2004 were immunised with the first dose at the
recommended age 11 to 14 months. Regarding cohort
2005, 148150 from 224371 (66%) vaccinated children
were immunised with the first dose at the recommended
age (Figure 1). Children of cohort 2004 had a median
age of 14 months at vaccination with monovalent vari-
cella vaccine (IQR: 12 to 17 months) and 23 months for
the first dose of MMRV vaccine (IQR: 22 to 23 months).
For children of cohort 2005, the median age was
13 months at vaccination with monovalent varicella vac-
cine (IQR: 12 to 15 months) and 14 months for the first
dose of MMRV vaccine (IQR: 12 to 18 months). Analy-
sis of data for cohort 2004 until an age of three years
revealed that additionally 50465 children (18% of all
Table 1 Varicella vaccination coverage (%) of children under two years of age in Germany
Vaccination coverage (%)
Cohort 2004 Cohort 2005 Difference
Federal State Varicella
vaccine
MMRV
vaccine
(2 doses)
Total Varicella
vaccine
MMRV
vaccine
(2 doses)
Total (p-value*)
Brandenburg 52 <1 52 39 14 53 0.402
Mecklenburg Western-Pomerania 63 <1 63 44 16 60 <0.001
Saxony 29 <1 29 48 <1 48 <0.001
Saxony-Anhalt 69 <1 69 53 11 64 <0.001
Thuringia 45 <1 45 46 3 49 <0.001
East Germany 47 <1 47 46 7 53 <0.001
Bavaria 19 <1 19 43 <1 43 <0.001
Bremen 8 <1 8 20 <1 21 <0.001
Hamburg 35 <1 35 53 8 61 <0.001
Lower Saxony 17 <1 17 46 6 52 <0.001
North Rhine-Westphalia 41 <1 41 48 5 53 <0.001
- North Rhine 52 <1 52 51 <1 51 <0.001
- Westphalia-Lippe 29 <1 29 44 11 55 <0.001
Saarland 48 <1 48 69 13 82 <0.001
Schleswig-Holstein 40 <1 40 37 22 59 <0.001
West Germany 30 <1 30 46 5 51 <0.001
Total 34 <1 34 46 5 51 <0.001
* p-value was calculated using uncorrected chi-square statistic
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were vaccinated between age 24 and 35 months, leading
to a vaccination coverage of 46% for children under
three years of age.
Coverage of vaccination costs
For cohort 2004, there is a significant association
between the level of vaccination coverage and the delay
of the introduction of cost coverage since the recom-
mendation of routine varicella vaccination in July 2004
(Spearman’s rho = -0.8164; p < 0.001) (Figure 2). The
level of vaccination coverage of cohort 2005 and the
delay of the introduction of cost coverage were not
significantly associated (Spearman’s rho = -0.2974;
p = 0.324) (Figure 3).
Discussion
We determined varicella vaccination coverage of statu-
tory health insured under two-year-old children. The
results show a significant increase in vaccination cover-
age from cohort 2004 to cohort 2005. Availability of the
tetravalent MMRV vaccine since 2006 might have influ-
enced the acceptance of varicella vaccination. Regional
studies in Bavaria and Schleswig-Holstein have also
shown an increase in varicella vaccination coverage in
young children [11,20]. Population-based incidence of
varicella is not available in Germany but data of the var-
icella sentinel surveillance system showed a steady
decrease in the number of varicella cases per reporting
physician and month between April 2005 and March
2009. The decrease has been observed in all age groups,
in particular for children at 0 to 4 years of age [13].
Regional differences in vaccination coverage could be
observed. Children in former Eastern Germany had sig-
nificantly higher varicella vaccination coverage than
children in former Western Germany. Vaccinations
were mandatory for school and kindergarten entry in
the former German Democratic Republic and therefore
a higher acceptance of vaccinations can still be
assumed. It has been shown that coverage rates for
other vaccinations e.g. for measles are higher in Eastern
Germany as well [21]. However, vaccination coverage of
children in former Western Germany is increasing [22].
Figure 1 Age of vaccinated children under two years of age at day of varicella vaccination, cohort 2004 and 2005.
Table 2 Type of varicella vaccine and number of doses
administered to children under two years of age in
Germany
No. of children (%)
Cohort
2004
Cohort
2005
Statutory health insured children 415.078
(100)
404.988
(100)
Children vaccinated with varicella monovalent
vaccine
- one dose 138.645
(33)
181.861
(45)
- two doses 1.221 (<1) 4.338 (1)
- more than two doses 18 (<1) 86 (<1)
Children vaccinated with MMRV vaccine
- one dose 281 (<1) 16.642 (4)
- two doses 95 (<1) 21.718 (5)
- more than two doses 1 (<1) 297 (<1)
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cohort 2004 was significantly associated with the delay
in cost coverage since the introduction of the routine
varicella programme in July 2004. Our results highlight
the importance of vaccinations that are free of charge
when aiming for high vaccination coverage. Similar
findings were published by the Working Group on
Measles and Varicella, showing that sentinel physicians
in regions with early cost coverage administered more
varicella vaccines than physicians in a region with cost
coverage from season 2006/2007 on [13]. International
studies have also shown that vaccinations that are free
of charge are an important factor in the decision for
vaccinations [23].
Another factor that influenced regional differences in
vaccination coverage was the delay in the availability of
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Figure 3 Varicella vaccination coverage (%) of cohort 2005 in Germany, stratified by Federal State and time points of introduction of
cost coverage for varicella vaccination by Health Insurance Funds.
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Figure 2 Varicella vaccination coverage (%) of cohort 2004 in Germany, stratified by Federal State and time points of introduction of
cost coverage for varicella vaccination by Health Insurance Funds.
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Page 5 of 7specific codes for reimbursement, even when costs for
the varicella vaccine were covered. When routine vari-
cella vaccination was recommended in July 2004, a spe-
cific code for the monovalent vaccine has been
introduced in North Rhine as late as October 2004. And
when the MMRV vaccine became available in July 2006,
some ASHIP regions had a specific code for this vaccine
only since 2007 (Bremen, Saxony, Saxony-Anhalt, Saar-
land and Thuringia) or 2008 (Bavaria and North Rhine).
Since epidemiological analysis of data is based on these
codes, a higher number of children than reported in our
study might have been vaccinated in the second half of
2006 and 2007.
More than half of the vaccinated children of cohort
2 0 0 4a n dt w ot h i r d so fc o h o r t2 0 0 5w e r ei m m u n i s e da t
the recommended age by STIKO. The remaining vacci-
nated children were older than recommended at date of
vaccination. This might be explained by catch-up vacci-
nations in the years after introduction of the routine
varicella programme. Our findings are in line with other
studies from Germany [21,24]. The percentage of chil-
dren vaccinated at the recommended age has been con-
stantly increasing since 1996 and the use of
combination vaccines seems to contribute to this devel-
opment [21,25]. The children in cohort 2004 were
increasingly vaccinated against varicella at age 24 and 25
months, resulting in a vaccination coverage of 46% at
the age of under three years. Around this age, a well-
baby check-up is scheduled and it seems that physicians
use this check-up for catch-up vaccinations. The median
time interval between two doses of MMRV vaccine was
28 weeks for cohort 2004 and 15 weeks for cohort 2005.
Thus, physicians followed the manufacturer’si n s t r u c -
tions regarding the time period of a minimum of six
weeks between the two doses.
It has been shown that secondary data from ASHIPS
can be used to determine vaccination coverage [15,26].
However, one has to keep in mind that routine health
data are primarily collected for reimbursement purposes.
Thus, there are limitations in the use of these data when
vaccination coverage is determined. In our study, the
delay in the availability of specific codes for reimburse-
ment of varicella vaccines had influenced the level of
regional vaccination coverage. It is crucial to choose an
appropriate denominator for routine health data. In our
study, the numbers of statutory health insured children
of the birth cohorts 2004 and 2005 were used to deter-
mine varicella vaccination coverage. Another valid
method is to use contacts between patient and physi-
cians, if known [26]. The data of ASHIPs only relate to
statutory health insured children. We assume that cov-
erage of the remaining 14 to 15%, who are mostly pri-
vately health insured, is equally high because private
health insurances usually cover the costs of
recommended vaccinations. We presented varicella vac-
cination coverage for 12 from 16 German Federal States.
All 17 ASHIPs are collaborating partners of the project
at RKI. Thus, in future, nationwide data on vaccinations
will be available.
Conclusions
Our study shows increasing varicella vaccination cover-
age of young children, indicating a growing acceptance
of the routine varicella vaccination programme by the
parents and physicians. We recommend further moni-
toring of varicella vaccination coverage using data from
ASHIPs to investigate implementation of the routine
vaccination programme over time. Data from ASHIPs
can also be used for continuous monitoring of other
childhood vaccinations that are recommended in
Germany.
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